Better Screening for Prostate Cancer
Impact Life • Do What’s Right • Innovate Together • Build Community
Prostate Cancer is the second deadliest cancer for American men. More than 191,930 men will be diagnosed in 2020 and 33,330 will die from Prostate Cancer. Simultaneously, it is overdiagnosed and overtreated in men with indolent (less aggressive) prostate cancer. This leads to unnecessary treatments such as prostatectomy and radiation therapy.
PSA: An Imperfect Screening Tool
Prostate Specific Antigen or PSA is currently the standard test used for prostate cancer screening. However, it has several shortcomings, including:
Screening is Declining
Because the PSA test is no longer recommended, screening rates of men in the United States have declined. Lower screening reduces the overdiagnosis and overtreatment of Prostate Cancer as intended by the recommendation. However, by screening less men for Prostate Cancer, the aggressive cancers will also be missed. This will trigger more deaths that could have been avoided.
Let's not abandon screening; let's build a better screening test.
Why Seminal Fluid?
The prostate produces about 30% of the total volume of seminal fluid; thus giving it the distinct advantage of having direct, non-invasive access to abundant prostate cancer biomarkers. These important biomarkers would be undetectable at the same stage of cancer development by other sample types such as blood or urine.
Furthermore, our test will be available to be collected in the comfort of ones own home and shipped back to the lab. The ease of use and widespread availability of this test will allow more men to be tested and more affordably.
The Seminal Fluid Advantage
Over 250,000X more biomarker in Seminal Fluid than in blood serum.